No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
EW240517C87500
- 0.50
- -0.30-37.50%
15min DelayTrading May 13 11:15 ET
0.60High0.45Low
0.60Open0.80Pre Close3 Volume1.19K Open Interest87.50Strike Price155.00Turnover26.11%IV3.62%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier4DDays to Expiry0.50Time Value100Contract SizeAmericanOptions Type0.2409Delta0.1247Gamma64.69Leverage Ratio-0.0902Theta0.0025Rho15.59Eff Leverage0.0298Vega
Intraday
- 5D
- 1D
News
India's Meril Files EU Antitrust Complaint Against Edwards: Report
Express News | Edwards Lifesciences Faces EU Antitrust Complaint From Rival Meril Over Patent Practices; Meril Aims To Challenge Competition Through EU Action
Express News | Edwards Lifesciences Targeted In EU Antitrust Complaint; Meril's Complaint Singles Out Edwards Lifesciences' Patent Practices; Edwards Says Meril's EU Complaint Aims To Circumvent Competition, National Court Decisions
Express News | Meril's EU Complaint Aims to Circumvent Competition, National Court Decisions, Edwards Says
Express News | Meril's Complaint Singles Out Edwards Lifesciences' Patent Practices
Express News | Edwards Lifesciences Targeted in EU Antitrust Complaint, Rival Meril Says
Comments
Edwards Lifesciences' impressive ROCE history and its ability to generate high returns on increasing amounts of capital employed indicate strong fundamentals. This warrants further research into the stock despite it being more 'expensive' than before.
Edwards Lifesciences (NYSE:EW) Is Aiming To Keep Up Its Impressive ReturnsAnalysts reconfirmed revenue and earnings forecasts for Edwards Lifesciences, indicating no major change in business expectations following recent results. The price target increase suggests analysts believe the business's intrinsic value is improving.
Investors banking on Edwards Lifesciences' high P/E ratio might face a challenge as the firm's predicted market-aligned growth hints at a potential share price decline.
Here are the top gap ups and downs for the stocks with a market cap above $5 billion after market closed (gaps range from large to small):
Gap Ups
1. $Align Technology(ALGN.US$ - up 11.5%
2. $Textron(TXT.US$ - up 5.2%
3. $STMicroelectronics(STM.US$ - up 4.1%
4. $Lam Research(LRCX.US$ - up 3.9%
5. $RELX PLC(RELX.US$ - up 3.1%
6. $Royal Caribbean(RCL.US$ - up 3.1%
7. $Micron Technology(MU.US$ - up 3.1%
8. $Western Digital(WDC.US$ - up 2.9...
Gap Ups
1. $Align Technology(ALGN.US$ - up 11.5%
2. $Textron(TXT.US$ - up 5.2%
3. $STMicroelectronics(STM.US$ - up 4.1%
4. $Lam Research(LRCX.US$ - up 3.9%
5. $RELX PLC(RELX.US$ - up 3.1%
6. $Royal Caribbean(RCL.US$ - up 3.1%
7. $Micron Technology(MU.US$ - up 3.1%
8. $Western Digital(WDC.US$ - up 2.9...
+17
18
Pre-Market Stock Movers
Gapping up
$Align Technology(ALGN.US$
(The orthodontics company surged 14% after posting adjusted earnings late Wednesday of $2.22 per share for the second quarter, beating estimates of $2.03 per share, according to Refinitiv. Revenue for the quarter also topped estimates, and revenue guidance for the year was above analyst expectations.)
$Meta Platforms(META.US$
(The Facebook parent jumped ne...
Gapping up
$Align Technology(ALGN.US$
(The orthodontics company surged 14% after posting adjusted earnings late Wednesday of $2.22 per share for the second quarter, beating estimates of $2.03 per share, according to Refinitiv. Revenue for the quarter also topped estimates, and revenue guidance for the year was above analyst expectations.)
$Meta Platforms(META.US$
(The Facebook parent jumped ne...
17
Read more